Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line
Esophageal Cancer by AJCC V8 Stage
DRUG: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib|DRUG: Camrelizumab+Chemotherapy→Camrelizumab
PFS[Progression-Free Survival], Time from randomization to first radiographic disease progression (RECIST 1.1 criteria) or death, whichever occurs first., up to 2 year
OS[Overall Survival], Time from randomization to the subject's death. At the end of the study, if the subject is still alive, the last known date of survival of the subject will be the date of deletion., up to 2 year|ORR[Objective Response Rate], Proportion of subjects in the analysis population who achieved complete response (CR) or partial response (PR) based on RECIST 1.1 criteria., up to 1 year|DCR[Disease Control Rate], Proportion of subjects in the analysis population who achieved complete response (CR) , partial response (PR) or stable disease(SD) based on RECIST 1.1 criteria., up to 1 year|TTR[Time to response], Time from randomization to firstly achieve CR or PR based on RECIST 1.1 criteria., up to 1 year|DoR[Duration of response], For subjects who achieved remission, the time from first achieving CR or PR to disease progression or death, whichever occurred earlier., up to 2 year|AEs[Adverse events], The incidence and severity of adverse events (AE) and serious adverse events (SAE) were determined according to NCI-CTCAE v5.0 criteria., up to 2 year
To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line